Swedbank Ab Astrazeneca PLC Transaction History

Swedbank Ab

$77.1 Billion
Q3 2024

A detailed history of Swedbank Ab transactions in Astrazeneca PLC stock. As of the latest transaction made, Swedbank Ab holds 2,705,757 shares of AZN stock, worth $174 Million. This represents 0.27% of its overall portfolio holdings.

Number of Shares

2,705,757

Previous 2,670,757 1.31%

Holding current value

$174 Million

Previous $208 Million 1.22%

% of portfolio

0.27%

Previous 0.28%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 15, 2024	BUY	$76.67 - $87.62 $2.68 Million - $3.07 Million	35,000 Added 1.31%	2,705,757 $211 Million
Q2 2024 Jul 18, 2024	SELL	$66.81 - $80.83 $5.11 Million - $6.18 Million	-76,500 Reduced 2.78%	2,670,757 $208 Million
Q1 2024 May 21, 2024	BUY	$61.03 - $69.57 $168 Million - $191 Million	2,747,257 New	2,747,257 $186 Billion
Q2 2023 Dec 09, 2024	BUY	$69.91 - $75.81 $16.6 Million - $18 Million	238,000 Added 9.85%	2,653,757 $190 Million
Q1 2023 Dec 09, 2024	BUY	$63.15 - $71.6 $12,630 - $14,319	200 Added 0.01%	2,415,757 $168 Million
Q4 2022 Dec 09, 2024	BUY	$54.21 - $70.44 $5.59 Million - $7.26 Million	103,100 Added 4.46%	2,415,557 $164 Million
Q2 2022 Dec 09, 2024	BUY	$59.26 - $71.14 $6.6 Million - $7.93 Million	111,420 Added 5.06%	2,312,457 $153 Million
Q1 2022 Dec 09, 2024	SELL	$55.72 - $67.12 $9.94 Million - $12 Million	-178,400 Reduced 7.5%	2,201,037 $146 Million
Q4 2021 Dec 09, 2024	SELL	$54.02 - $63.83 $11.4 Million - $13.5 Million	-211,000 Reduced 8.15%	2,379,437 $139 Million
Q3 2021 Dec 09, 2024	BUY	$55.56 - $60.79 $144 Million - $157 Million	2,590,437 New	2,590,437 $156 Million

Others Institutions Holding AZN

# of Institutions

1,361

Shares Held

475M

Call Options Held

5.39M

Put Options Held

3.75M

View Full List

About ASTRAZENECA PLC

Ticker AZN
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 3,099,020,032
Market Cap $200B
Description
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...

More about AZN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Swedbank Ab, based on Form 13F filings with the SEC.

News

Stay updated on Swedbank Ab with notifications on news.

Account